Related Experiment Videos

Mithramycin cannot bind to left-handed poly(dG-m5dC) in the presence of Mg2+ ion

C Demicheli1, A Garnier-Suillerot

  • 1Laboratoire de Chimie Bioinorganique, LPCB (UA CNRS 198), UFR Biomédicale, Bobigny, France.

Biochemical and Biophysical Research Communications
|May 31, 1991
PubMed

Insights

Mithramycin, an antitumor drug, binds DNA by forming a complex with double-strand DNA. This study shows Mithramycin binds right-handed DNA but not left-handed DNA in the presence of magnesium ions.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Anticancer Drug Research

Background:

  • Mithramycin (MTR) is a known antitumor compound.
  • MTR functions by inhibiting RNA and DNA polymerase.
  • It forms a non-covalent complex with double-strand DNA in the presence of divalent cations.

Purpose of the Study:

  • To investigate the binding mechanism of Mithramycin (MTR) to different DNA conformations.
  • To determine the influence of magnesium ions (Mg2+) on MTR-DNA interaction.
  • To elucidate the stereochemical requirements for MTR binding to DNA.

Main Methods:

  • Studied the interaction of Mithramycin with poly(dG-m5dC) DNA.
  • Utilized magnesium ions (Mg2+) as a divalent cation.
  • Compared binding to right-handed versus left-handed DNA conformations.

Main Results:

  • Mithramycin (MTR) binds to right-handed poly(dG-m5dC) in the presence of Mg2+.
  • MTR forms a dimer complex with right-handed DNA.
  • MTR does not bind to left-handed poly(dG-m5dC) under these conditions.

Conclusions:

  • The binding of Mithramycin to DNA is conformation-dependent.
  • Magnesium ions are crucial for MTR's ability to bind right-handed DNA.
  • MTR's antitumor activity may be linked to its specific binding to right-handed DNA structures.

Related Concept Videos